#ASH18: Acceleron and Celgene take center stage with a pair of PhIIIs for luspatercept they believe will back up $2B-plus in revenue projections
Ever since Acceleron and its needy partners at Celgene touted positive Phase III top-line results for luspatercept for patients suffering from myelodysplastic syndrome as well as beta thalassemia, analysts have been trying to figure out just how good the numbers need to be in order to live up to the companies’ estimates this drug will deliver $2 billion-plus in peak sales.
So you better believe that their appearance in the showcase plenary session at ASH on Saturday was keeping plenty of people on their toes.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.